Molecular assay kits
Methods, kits, and compositions for evaluating the quality of nucleic acids within a biological sample for analysis in a molecular assay are provided.
1. A kit for evaluating a biological sample containing potentially degraded DNA, comprising a control amplification reagent and a target amplification reagent, wherein the control amplification reagent comprises two or more pairs of amplification oligonucleotides capable of amplifying a medium chain acyl-coenzyme A dehydrogenase (MCAD) nucleic acid molecule or a complement thereof, and wherein the target amplification reagent comprises one or more pairs of amplification oligonucleotides capable of amplifying a non-MCAD target gene of interest or a complement thereof,
wherein each pair of control amplification reagent amplification oligonucleotides is capable of amplifying a region of the MCAD nucleic acid molecule to produce an MCAD amplicon, and wherein each MCAD amplicon produced by each pair of amplification oligonucleotides is detectably distinguishable from the MCAD amplicon produced by each other pair of amplification oligonucleotides on the length of each MCAD amplicon, and
wherein one or more of the amplification oligonucleotides is/are labeled.
2. The kit of claim 1 , comprising three or more pairs of amplification oligonucleotides capable of amplifying the MCAD nucleic acid molecule or a complement thereof.
3. The kit of claim 1 , wherein each of the two or more pairs of control amplification reagent amplification oligonucleotides comprises a sense amplification oligonucleotide and an antisense amplification oligonucleotide, and wherein the sense amplification oligonucleotide of each of the two or more pairs of control amplification reagent amplification oligonucleotides comprises the same oligonucleotide sequence.
4. The kit of claim 1 , wherein each of the two or more pairs of control amplification reagent amplification oligonucleotides comprises a sense amplification oligonucleotide and an antisense amplification oligonucleotide, and wherein the antisense amplification oligonucleotide of each of the two or more pairs of control amplification reagent amplification oligonucleotides comprises the same oligonucleotide sequence.
5. The kit of claim 1 , wherein the biological sample comprises a tissue sample.
6. The kit of claim 5 , wherein the tissue sample comprises a formalin-fixed paraffin-embedded (FFPE) tissue sample.
7. The kit of claim 1 , wherein the target amplification reagent comprises a reagent specific for wild-type or mutant v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), phosphatidylinositol 3-kinase (PIK3CA), phosphatase and tensin homolog (PTEN), v-akt murine thymoma viral oncogene homolog (AKT), anaplastic lymphoma kinase (ALK), mast/stem cell growth factor receptor (c-Kit), neuroblastoma RAS viral oncogene homolog (NRAS), met proto-oncogene hepatocyte growth factor receptor (c-Met), prostate cancer gene 3 (PCA3), prostate specific membrane antigen (PSMA), prostate specific antigen (PSA), tumor protein 53 (TP53), Echinoderm microtubule-associated protein-like 4 (EML4), EML4-ALK fusions, androgen regulated gene-ETS family member gene fusions, RAF gene fusions, breakpoint cluster region −V-abl Abelson murine leukemia viral oncogene homolog 1 fusions (BCR-Abl), cytochrome P450 2D6 (CYP2D6), cytochrome P450 2C19 (CYP2C19), cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), thiopurine methyltransferase (TMPT), bilirubin UDP-glucuronosyltransferase isozyme 1 (UGT1A1), and/or ATP-binding cassette sub-family B member 1 (ABCB1), or combinations thereof.